Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.34 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.34 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.34 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16747679 | 0.79 | KIF11 (0.56) | KIF11TAAR1ALDH1A1TSHRCES2 | |
| SCHEMBL14998069 | 0.79 | KIF11 (0.56) | KIF11TAAR1ALDH1A1TSHRCES2 | |
| SCHEMBL1745119 | 0.79 | KIF11 (0.44) | KIF11GSK3BPTPN1TAAR1ALDH1A1 | |
| SCHEMBL28847040 | 0.79 | RARB (0.47) | KIF11TSHRMAOBAOC3 | |
| SCHEMBL5894329 | 0.79 | IDO1 (0.35) | ALDH1A1IDO1CES2 | |
| SCHEMBL7039272 | 0.79 | CYP2C19 (0.54) | KIF11TAAR1IDO1MAOBAOC3 | |
| SCHEMBL3943848 | 0.79 | KIF11 (0.44) | KIF11TAAR1ALDH1A1TSHRIDO1 | |
| Hydrochloric Acid SCHEMBL21803745 | 0.78 | BLM (0.55) | KIF11TAAR1IDO1MAOBAOC3 | |
| SCHEMBL5482239 | 0.76 | KIF11 (0.41) | KIF11TAAR1ALDH1A1TSHRIDO1 | |
| SCHEMBL4020265 | 0.76 | GABRP (0.44) | KIF11TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023229295-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING PHENYLPROPENE DERIVATIVE AS ACTIVE INGREDIENT | 재단법인 대구경북첨단의료산업진흥재단 | 2023-11-30 | — | — | WO | disclosed |
| EP-1940811-B1 | HETEROCYCLIC COMPOUNDS WITH CARBOXYL ISOSTERE GROUPS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2014-02-26 | — | — | EP | disclosed |
| US-8362011-B2 | Tricyclic triazolic compounds | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-01-29 | — | — | US | disclosed |
| US-8362011-B2 | Tricyclic triazolic compounds | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-01-29 | — | — | US | disclosed |
| EP-2227476-B1 | TRICYCLIC TRIAZOLIC COMPOUNDS | ESTEVE LABOR DR (ES) | 2011-09-07 | — | — | EP | disclosed |
| US-7998988-B2 | Biphenyl compounds useful in the treatment or prevention of cardiovascular disorders | BAYER SCHERING PHARMA AKTIENGELLSCHAFT (DE) | 2011-08-16 | — | — | US | disclosed |
| US-20100298309-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2010-11-25 | — | — | US | disclosed |
| US-20100298309-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2010-11-25 | — | — | US | disclosed |
| US-20100267778-A1 | Diphenyl ether compound, process for producing the same, and use | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2227476-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-09-15 | — | — | EP | disclosed |
| US-20090227640-A1 | Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2009-09-10 | — | — | US | disclosed |
| EP-2070933-A1 | Tricyclic triazolic compounds | Laboratorios del Dr. Esteve S.A. (ES) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009071657-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-11 | — | — | WO | disclosed |
| EP-1940811-A1 | HETEROCYCLIC COMPOUNDS WITH CARBOXYL ISOSTERE GROUPS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007045366-A1 | HETEROCYCLIC COMPOUNDS WITH CARBOXYL ISOSTERE GROUPS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-04-26 | — | — | WO | disclosed |
| EP-1661879-A1 | DIPHENYL ETHER COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227640-A1 | Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases | TNNI3, PC, TNNT2 | KIF11 4835/4885GSK3B 973/4885PTPN1 3484/4885 |
| US-20100267778-A1 | Diphenyl ether compound, process for producing the same, and use | PPARG, PPARD, PPARA | KIF11 4556/4885GSK3B 1472/4885PTPN1 1148/4885 |
| US-20100298309-A1 | TRICYCLIC TRIAZOLIC COMPOUNDS | SIGMAR1, OPRK1, OPRM1 | KIF11 4269/4885GSK3B 1077/4885PTPN1 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.